Who owns Africa’s biological data?

The question of who owns and controls Africa's vast biological resources has emerged as one of the continent's most pressing policy challenges, with significant implications for multinational corporations, research institutions, and investors seeking to operate across African markets. While genetic material and biological data are often treated as freely accessible research commodities in global scientific circles, African nations are increasingly asserting that these resources constitute sovereign national assets requiring explicit benefit-sharing agreements and regulatory oversight. Africa holds approximately 30% of the world's remaining biodiversity, yet the continent has historically captured minimal economic value from the commercialization of its biological resources. Pharmaceutical companies, agricultural biotechnology firms, and cosmetics manufacturers have long extracted genetic material and traditional knowledge from African ecosystems and communities with limited compensation flowing back to source nations or local populations. This asymmetry has fueled growing momentum across African governments to establish robust regulatory frameworks governing bioprospecting activities and data ownership. The economic stakes are substantial. The global biotechnology market derived from biological materials is valued at hundreds of billions of dollars annually. African nations are recognizing that their genetic resources—including unique plant species, microbial strains, and traditional medicinal knowledge—represent significant untapped revenue sources. Countries including Kenya, South Africa,